DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia.
Escherich CS, Moriyama T, Li Z, Hsiao YC, Yang W, Li Y, Reyes N, Walker M, Budhraja A, Bhatara S, Diaz-Flores E, Stock W, Paietta E, Konopleva MY, Kornblau SM, Litzow MR, Inaba H, Pui CH, Opferman JT, Loh ML, Yu J, O'Brien MM, Evans WE, Yang JJ.
Escherich CS, et al. Among authors: yang jj, yang w.
Blood. 2025 Mar 13;145(11):1182-1194. doi: 10.1182/blood.2024026085.
Blood. 2025.
PMID: 39791601